New Developments in Ovarian Cancer Treatment Are Showing Promise

September 14, 2018 4:29 pm

Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.

But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more

The Future of Ovarian Cancer: PARP Inhibition ‘Leading the Way’

July 6, 2018 8:58 pm
By Brielle Urciuoli
PARP inhibitors have made for new and exciting treatment options for ovarian cancer, but there is still much more work to be done, according to Dennis J. Slamon, M.D., Ph.D.

Slamon, who is the director of both

Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

Scientists Identify Why Some May Be Resistant To PARP Inhibitor Drugs

May 21, 2018 6:33 pm

A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.

The … Read more

New Immunotherapy Shows Promise Against Ovarian Cancer

April 10, 2018 8:57 pm

Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.

One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more

SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

7 Key Cancer Trends For 2018

January 3, 2018 6:48 pm

By: Elaine Schattner

I expect progress. Here’s my list of major trends and issues that will affect the lives of cancer patients in 2018:

1. Less chemotherapy

recent report finds that among patients with the most common form of … Read more

FDA Grants Priority Review for Rucaparib

December 28, 2017 8:08 pm

The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more

Future Focus: Ovarian Cancer in 2018 and Beyond

December 14, 2017 3:49 pm

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further … Read more

Webinar: PARP Inhibitors: What You Need to Know

October 18, 2017 7:32 pm

Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.

There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more

Another Win for PARP Inhibition in Ovarian Cancer

September 12, 2017 4:09 pm

Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.

Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

Pairing PARP Inhibitors With Other Drug Types the Next Frontier for BRCA-Mutated Ovarian Cancers

June 13, 2017 6:35 pm

The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more

Ovarian Cancer Patients Actively Seeking PARP Inhibitor Therapy, Expert Says

May 15, 2017 5:19 pm

In the treatment of advanced ovarian cancer, PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), are stealing the limelight, explains Dennis Scribner, MD.

In an interview with Targeted Oncology, Scribner, a gynecologic oncologist at Arizona Oncology, discussed … Read more

Ending a Dry Spell of Years Without Treatment for Ovarian Cancer

May 3, 2017 7:04 pm

Teri Woodhull is decidedly proactive. A strong family history of breast cancer led her to undergo a preventive bilateral mastectomy at age 30. Seventeen years later, she was diagnosed with stage 3b high-grade serous epithelial ovarian cancer.

“I do have … Read more

PARP Inhibitor Approvals Offer Ovarian Cancer Patients New Hope

April 18, 2017 5:20 pm

The ovarian cancer treatment paradigm underwent another transformation near the end of 2016 with the FDA approval of the PARP inhibitor rucaparib (Rubraca) for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of … Read more

PARP Inhibitor Active in BRCA Subgroups

March 14, 2017 5:52 pm

Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.

Results showed a median PFS of … Read more

Tesaro Opens Expanded Program of PARP inhibitor for U.S. Ovarian Cancer Patients

January 18, 2017 7:31 pm

Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more